Oculomucocutaneous syndrome
| Oculomucocutaneous syndrome | |
|---|---|
| Specialty | Ophthalmology |
 | This article may be too technical for most readers to understand. (February 2021) |
Oculomucocutaneous syndrome is characterized by keratoconjunctivitis sicca (dry eyes) and the resulting scarring, fibrosis, metaplasia, and shrinkage of the conjunctiva.[1] It is a drug side effect observed in practolol and eperisone. It is speculated that antibodies against drug metabolites cause the syndrome.[2]
References[edit]
- ^ Wright, P (Mar 15, 1975). "Untoward effects associated with practolol administration: oculomucocutaneous syndrome". British Medical Journal. 1 (5958): 595–8. doi:10.1136/bmj.1.5958.595. PMC 1672788. PMID 1125623.
- ^ Amos, HE; Lake, BG; Artis, J (Feb 18, 1978). "Possible role of antibody specific for a practolol metabolite in the pathogenesis of oculomucocutaneous syndrome". British Medical Journal. 1 (6110): 402–4. doi:10.1136/bmj.1.6110.402. PMC 1602979. PMID 146533.
 | This cutaneous condition article is a stub. You can help Wikipedia by expanding it. |